4:04 AM
 | 
Sep 05, 2018
 |  BioCentury  |  Finance

Fulcrum’s genetic levers

Why Foresite led an $80M series B round for gene regulation play Fulcrum.

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round.

Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors also participated.

Third Rock Ventures launched Fulcrum in 2016 to develop small molecules that modulate targets responsible for regulating gene expression (see “Leverage Over Genes”).

The company obtains diseased cells...

Read the full 391 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >